Insomnia: evidence-based mechanisms, health impacts, diagnosis, and therapeutic strategies for sleep-wake dysregulation

Insomnia is a disorder of impaired sleep quantity and/or quality that occurs despite adequate opportunity for sleep and is accompanied by daytime consequences (e.g., fatigue, impaired attention, mood disturbance). Clinically, insomnia can be characterized as difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, or a combination of these patterns. Epidemiologically, insomnia is common across age groups and often coexists with psychiatric conditions (such as anxiety and depression), neurologic disorders, pain syndromes, and cardiometabolic diseases.

Physiologically, insomnia reflects dysregulation of the sleep-wake system. Sleep initiation depends on a balance between circadian drive (homeostatic sleep pressure and circadian alerting signals) and arousal systems. In insomnia, hyperarousal is frequently observed: increased physiological activation (elevated sympathetic activity, heightened cortisol secretion in some subtypes), cognitive hypervigilance about sleep, and maladaptive conditioning to the bed as a cue for wakefulness. Neurobiologically, insomnia has been associated with altered functional connectivity in frontoparietal attention networks, changes in limbic and stress-related circuits, and dysregulation of neurotransmitter systems involved in arousal regulation, including GABAergic and serotonergic pathways.

The cognitive model emphasizes perpetuating factors: sleep-related worry (“Will I sleep tonight?”), selective attention to nocturnal awakenings, and safety behaviors that fragment sleep (e.g., spending excessive time awake in bed, napping to compensate). When sleep is irregular or fragmented, homeostatic sleep pressure becomes less predictable, further destabilizing the circadian timing of sleep. This can produce a feedback loop in which insomnia both reflects and drives stress physiology.

Untreated insomnia carries meaningful health risks. Daytime impairments include reduced psychomotor performance, slowed reaction time, decreased executive function, and worse emotional regulation. Chronic insomnia is associated with increased risk of hypertension and adverse cardiometabolic outcomes, partly mediated by sustained stress hormone elevations, inflammatory signaling changes, and disturbed glucose metabolism. Depression and anxiety are more prevalent among people with insomnia, and insomnia can also exacerbate existing psychiatric disease. Additionally, insomnia worsens pain perception through altered descending inhibitory pathways and heightened central sensitization.

Diagnosis requires an insomnia-focused history, because sleep complaints are common and may be secondary to other sleep disorders. A careful assessment should address duration, frequency, sleep pattern, bedtime and wake time, total sleep time, awakenings, and daytime impairment. Clinicians should screen for obstructive sleep apnea (snoring, witnessed apneas, morning headaches), restless legs syndrome (urge to move legs, circadian pattern), circadian rhythm sleep-wake disorders (delayed or advanced sleep timing), medication effects (e.g., stimulants, corticosteroids), substance use (caffeine, nicotine, alcohol), and medical comorbidities.

Tools often used include sleep diaries and validated questionnaires such as the Insomnia Severity Index, which help quantify baseline severity and track treatment response. Polysomnography is not routinely required for uncomplicated insomnia but may be indicated if another sleep disorder is suspected or if treatment resistance occurs. Actigraphy can support circadian and behavioral assessment over time.

First-line treatment for chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I). CBT-I targets the perpetuating mechanisms through multiple components: stimulus control (strengthening bed-and-sleep association), sleep restriction therapy (consolidating sleep by limiting time in bed to approximate actual sleep time, then gradually expanding), cognitive restructuring (reducing catastrophic beliefs and sleep-related worry), and sleep hygiene education (addressing caffeine timing, light exposure, and behavioral rhythms). These interventions reduce hyperarousal and improve sleep efficiency without reliance on sedative pharmacology.

Pharmacologic therapy may be considered for short-term relief in selected patients, typically as an adjunct while CBT-I is initiated. Options include hypnotics such as non-benzodiazepine receptor agonists (Z-drugs) and orexin receptor antagonists; for some patients, certain low-dose antidepressants with sedative properties are used off-label. Medication selection should consider contraindications, comorbidities, fall risk, and potential interactions. Risks include next-day impairment, tolerance, dependence potential, and complex sleep behaviors with some agents.

Addressing comorbidities is critical. Treating anxiety, depression, chronic pain, and sleep-disordered breathing can substantially improve insomnia outcomes. Behavioral interventions are particularly effective when insomnia is driven by stress, maladaptive conditioning, or inconsistent sleep schedules.

If you experience persistent sleep difficulty, particularly with marked daytime dysfunction, evaluation by a clinician is recommended to rule out secondary causes and to implement evidence-based therapy. Source: [@Tkyk29]